HemaSphere (Jun 2022)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

  • G. Garcia-Manero,
  • E. S. Winer,
  • D. J. DeAngelo,
  • S. Tarantolo,
  • D. A. Sallman,
  • J. Dugan,
  • S. Groepper,
  • A. Giagounidis,
  • K. Götze,
  • K. H. Metzeler,
  • C.-C. Li,
  • L. Zhou,
  • E. Martinez,
  • M. Lane,
  • R. von Roemeling,
  • M. Bohme,
  • A. S. Kubasch,
  • A. Verma,
  • U. Platzbecker

DOI
https://doi.org/10.1097/01.HS9.0000843408.31385.3f
Journal volume & issue
Vol. 6
pp. 30 – 31

Abstract

Read online

No abstracts available.